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that the impact of upstream, horizontal, and downstream alliances on product development
depends on the degree of specialization of new firms' technological capabilities. Using a databaseHigh technology new firms have extensively used strategic alliances to gain access to knowledge,
resources and capabilities. However, given their inexperience and limited resources, these firms
are vulnerable to their more established partners' potential opportunism. This raises the
question: How can new firmsmaximize the benefits of these alliances while reducing their risks?
In this study, we address this question by drawing upon the capabilities perspective to propose
of biotechnology firms, the results support this argument even when different types of strategic
alliances are considered.
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New product development (NPD) and market introduction are important for high technology new firms' (HTNFs') successful
performance. Yet, developing, testing and commercializing new products can be costly and time consuming processes and their
outcomes are uncertain. As a result, many HTNFs have employed strategic alliances to gain the knowledge necessary to develop or
acquire the capabilities needed for NPD. Many of the alliances that HTNFs have formed have been with established industry
incumbents who possess the NPD-related resources, skills and expertise.
However, the need to access, acquire and assemble capabilities quickly may lead some HTNFs to join alliances under
unfavorable conditions that make alliances unstable and prone to failure. These alliances could increase the risk of expropriation of
the firm's own knowledge, undermining the new firms' competitive position. Reducing potential expropriation through thex: +49 89 2180 6284.
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218 C. Haeussler et al. / Journal of Business Venturing 27 (2012) 217–233careful selection of partners and the use of contracts can be costly and HTNFs may lack the experiences or resources to do so
effectively. HTNFs also lack the experience to manage the complexity of a large alliance portfolio and may not have the time, skills
or resources necessary to monitor their partners.
How can HTNFs use strategic alliances more productively and mitigate the risks of these alliances? We address this question
invoking the capabilities perspective to propose that the specialization of HTNFs' internal technological capabilities can
significantly mitigate potential alliance benefits and risks. Using a sample of 199 biotechnology firms from Germany and the UK,
we advance that the degree of specialization of a new firm's technological capabilities serves as a key organizational contingency
that influences the impact of strategic alliances on NPD. This focus departs from, and extends, the literature that highlights the
role of the alliance experience and slack resources as potential contingencies. Our results show that new firms can gain
significantly from joining alliances by carefully exploiting their own technological capabilities to mitigate the risks involved.
Given that different alliances can lead to different capabilities, we separate vertical upstream fromdownstream alliances that are
vertically vs. horizontally in order to assess the interdependencies between a new firm's technological capability specialization
and different types of alliances for a firm's NPD. Appreciating these varying effects can help HTNFs avoid unsuccessful alliances
that can depress their performance and threaten their survival. For managers and entrepreneurs, our results suggest that HTNFs
need to consider technological capabilities when selecting alliance partners. In particular, the specialization of HTNFs'
technological capabilities can significantly influence their ability to acquire or access capabilities from external sources and to
protect themselves from opportunistic partner behavior. The level of specialization of these capabilities, however, appears to
have different effects with different types of alliances.
Our results also underscore the importance of new firms' technological capabilities in gaining and capturing knowledge from
alliances and then using this knowledge in NPD. These capabilities and the level of HTNFs' specialization provide an important
basis to examine the benefits and risks associated with alliances of different types, an issue that deserves examination in future
studies in different high technology sectors. It is important also to identify and investigate the mechanisms by which HTNFs use
their technological capabilities to absorb knowledge from their alliance partners. We hope our findings encourage researchers to
pursue these issues.
2. Introduction
Turning research discoveries into marketable products and taking them to themarket is important for new firms operating in
high technology industries such as biotechnology, software, medical technology, and semiconductors. High technology new
firms (HTNFs) are small and medium-sized enterprises that are too young to have completed a full new product development
(NPD) cycle.3 These HTNFs often compete in dynamic and fierce environments (D'Aveni, 1994) and need to develop and
commercialize new products in order to exploit promisingmarket opportunities, generate needed cash flows, andmake a profit.
Yet, developing, testing and commercializing new products can be costly and time consuming processes, and their financial
outcomes uncertain. For example, NPD in the biopharmaceutical industry can generate several billion $US in revenues when a
new blockbuster drug is successfully introduced to themarket. Conversely, it can lead to the loss of hundreds of millions of $US if
the drug candidate fails during late development stages (DiMasi et al., 2003).
HTNFs are often unable to assemble the right mix of capabilities needed for NPD internally (Eisenhardt and Schoonhoven,
1996). Capabilities denote “the set of tangible and intangible assets that enable an organization to develop, make, and market
goods” (Gomes-Casseres, 1996: 30). In HTNFs, “those organizational capabilities or competencies which give rise to competitive
advantage are not “simple” assets, but compound asset structures which are built over time and are path dependent” (Deeds
et al., 1999: 213). For example, HTNFs' capabilities include the skills of their research teams, R&Dmanagement skills, and access
to external information sources (Deeds et al., 1999). Since it often takes years to develop these capabilities many HTNFs have
joined strategic alliances to develop the capabilities needed for NPD (Hagedoorn, 1993; Rothaermel and Deeds, 2004; Shan et al.,
1994; George et al., 2002; Patzelt et al., 2008). A strategic alliance is a cooperative relationship between two or more firms to
develop and commercialize a product (Deeds and Hill, 1996). Many of the alliances that HTNFs have formed have been with
established industry incumbentswho have strongNPD-related resources. HTNFs are desired partners for incumbents to allywith
in order to adapt to new technology and fill their product pipelines (Rothaermel, 2001).
However, the need to access, acquire and assemble capabilities quickly may lead some HTNFs to join alliances under
unfavorable conditions that make these alliances unstable and even prone to failure (Lerner and Merges, 1998; Lerner et al.,
2003). Indeed, in industries where NPD is based on specialized and complex organizational knowledge – defined as the explicit
(e.g., patents and publications) or tacit (e.g., research expertise and R&Dmanagement experience) knowledge embedded in the
people and processes of the HTNF (De Carolis and Deeds, 1999) – alliances can increase the risk of expropriation of the firm's own
knowledge (Pisano, 1990; Teece, 1986), potentially undermining the competitive position of new ventures. However, curbing
potential expropriation through careful partner selection and the use of contracts can be costly and HTNFs may lack the
experiences or resources to do so effectively (Lerner and Merges, 1998). HTNFs also lack the experience to manage the3 For example, in the software industry NPD might be completed within one year or less and a two-year old software firm might not qualify as a HTNF
However, in the biopharmaceutical industry NPD takes on average 12 years (DiMasi et al., 2003) and a 10-year old biopharmaceutical firm might still be a HTNF
While some HTNFs may not possess the skills needed for NPD in-house to market the resulting product, they may have licensed in/bought and marketed a
product from other firms..
.
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1996). New firms are often short on the resources, staff and expertise needed tomonitor their established partners and safeguard
against their potential opportunism.
The earlier discussion raises a question: How can HTNFs use alliances more productively and mitigate the risks of strategic
alliances? In this paper, we address this question by drawing on the capabilities perspective (Teece, 1986; Das and Teng, 2000)
and the literature on absorptive capacity (Cohen and Levinthal, 1990; Zahra and George, 2002) to propose that the specialization
of HTNFs' internal technological capabilities can significantly mitigate potential alliance benefits and risks. These capabilities
denote a firm's “ability to produce a component according to the required specification and schedule” (Hoetker, 2005: 78). Such
capabilities influence HTNFs' market success and define its competitive advantage (Kogut and Zander, 1992; Martin and
Salomon, 2003).
We propose that HTNFs can creatively exploit their technological capabilities to mitigate the risks of alliances while gaining
the knowledge required for NPD. Specifically, the degree of specialization of a new firm's technological capabilities serves as
a key organizational contingency that influences the impact of strategic alliances on NPD. To develop this argument, we
distinguish between types of alliances (e.g., Rothaermel and Deeds, 2006) to understand the differential effects of the
specialization of a firm's own technological capabilities on the benefits it gains while mitigating the risks of alliances. Given that
different alliances can give new firms different capabilities, we separate vertical upstream from downstream alliances that are
completed vertically vs. horizontally (Baum et al., 2000; Higgins and Gulati, 2006). Making this distinction allows us to assess
the interdependencies between a firm's technological capability specialization and the different types of alliances the firm
enters to promote NPD. Appreciating these effects can help HTNFs avoid unsuccessful alliances that can lower their performance
and threaten their survival (Alvarez and Barney, 2001).
To test our argument, we use a unique survey dataset on 199 biotechnology firms' alliance activities, their set of technological
capabilities, and NPD. In doing so, we contribute to the literature in three key ways. First, we introduce the degree of
specialization of an HTNF's technological capabilities as an organizational contingency that influences the potential impact of
strategic alliances on firm performance, specifically NPD. Prior research on new firm alliances has focused on alliance experience
(Hoang and Rothaermel, 2005; Rothaermel and Deeds, 2006) and slack resources (Lerner et al., 2003) to explain variance in the
benefits high technology firms gain from alliances. Second, the bulk of the literature has emphasized the benefits associatedwith
alliances, but with few exceptions (e.g., Baum et al., 2000) researchers have rarely analyzed the negative consequences of
alliances for the firms involved (Gulati, 1998). In this study, we show that entering into a new alliance can depress NPD and this
effect is contingent on the composition of the firm's internal technological capabilities. Consequently, HTNFs stand to gain from
joining alliances by carefully exploiting their own technological capabilities to mitigate the risks involved. Third, many existing
studies on HTNFs' alliances have failed to distinguish between the types of alliances (Rothaermel and Deeds, 2006). Our
distinction among upstream, horizontal, and downstream alliances enables us to assess the differential effects of the level of
specialization of internal technological capabilities on maximizing the upside potential and mitigating the risks of each type of
alliance for the new firms' NPD.
In the next section, we develop our theory and hypotheses. We then describe our sample and summarize the analysis and
results. After discussing key findings we recognize the study's limitations, identify promising avenues for future research, and
present our conclusion.
3. Theory and hypotheses
The capabilities perspective suggests that organizations need to have an appropriate stock of resources and capabilities and
use them effectively to gain a competitive advantage (Amit and Schoemaker, 1993; Teece et al., 1997). For many HTNFs, building
these capabilities internally can be a demanding and uncertain task. Capability development is an extremely complex, uncertain,
costly, and time consuming process (Teece et al., 1997; DiMasi et al., 2003). Recipes for successful capabilities are not known
beforehand. Further, having appropriate capabilities (e.g., for NPD) does not guarantee financial success. For example, only one
out of 5000 initial product candidates in the biopharmaceutical industry reaches themarket (Evans and Varaiya, 2003). Yet, high
technology industries are dynamic and fiercely competitive environments (D'Aveni, 1994), giving HTNFs little time to build the
various capabilities necessary to innovate and successfully commercialize their innovations. The need for multiple and often
complex capabilities as well as uncertainty surrounding the acceptance of new products have prompted HTNFs to join alliances
with other firms to acquire the different capabilities (Pisano, 1990; Zahra, 1996; Ahuja, 2000; Patzelt et al., 2008).
Success in gaining knowledge frompartners usually depends on the firm's absorptive capacity, defined as its ability to identify
and acquire knowledge from partners as well as understand and apply this knowledge for its own use (Cohen and Levinthal,
1990; Zahra and George, 2002). The development of absorptive capacity is a cumulative, path-dependent process that requires
significant and sustained investments (Nelson and Winter, 1982; Powell et al., 1996). Though studies suggest that R&D
expenditures can enhance absorptive capacity (Arora and Gambardella, 1994), we propose that the specialization of a firm's
technological capabilities may also significantly enrich this capacity and, as a result, may determine the benefits HTNFs derive
from alliances.
Technological capabilities are knowledge-based and build on HTNFs' experiences and prior learning (Leiblein andMiller, 2003;
Mayer and Nickerson, 2005).These capabilities denote a firm's “ability to produce a component according to the required
specification and schedule” (Hoetker, 2005: 78). In high technology sectors, this ability is usually evident in a firm's scientific
knowledge and competencies (Leiblein and Miller, 2003; Mayer and Nickerson, 2005). Therefore, in this study of HTNFs, we refer
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scientific techniques include DNA/RNA based techniques, proteins and molecules, cell tissue culture and engineering as well as
subcell techniques, process techniques, bioinformatics, and nanobiotechnology (OECD, 2005).
Some HTNFs might have a broad set of technological capabilities (a variety of scientific techniques), but others might have, or
specialize in, one or a few capabilities, building expertise in particular activities. Developing a broad set of capabilities is a time
consuming and costly task that requires coordination in the use of these capabilities. Conversely, narrow specialization may force
HTNFs to target only a small portion of their products' value chain, missing NPD opportunities. For instance, while the early steps of
the biopharmaceutical value chain (the research phase) require expertise in DNA/RNA based techniques and proteins/molecules,
later product development phases require knowledge in cell tissue cultures and bioinformatics to evaluate the data gained from
preclinical and clinical testing of the drug candidate.
Alliances of different types (vertical upstream, horizontal downstream and vertical downstream) might influence HTNFs' NPD
(captured by the number of products a firm develops over time, cf. Deeds et al., 1999), the benefits to be gained from each type
depends on the specialization of these firms' technological capabilities — as indicated in Fig. 1.
3.1. Technological capabilities and vertical upstream alliances
Alliances between HTNFs and established companies could be developed up or downstream, either vertically or horizontally.
Among the most common are vertical upstream alliances, which are cooperative relationships that HTNFs establish with
organizations upstream of their value chain (George et al., 2001). In science-based industries, HTNFs' upstream activities
typically require interacting with universities and public research institutions that conduct basic research (George et al., 2002).
Upstream alliances give HTNFs access to the valuable specialized, scientific, and technological knowledge needed to develop
new products (Deeds and Hill, 1996; Oliver and Liebeskind, 1998; Rothaermel and Deeds, 2006). Obtaining specialized
knowledge (Argyres and Liebeskind, 1998) and benefiting from knowledge spillovers (Owen-Smith and Powell, 2004) can
improve HTNFs' NPD in terms of speed andmeeting design criteria (Zucker et al., 2002). Accessing knowledge through upstream
alliances can also lower NPD costs (Kogut, 1988), allowing firms to allocate their financial resources amongmore projects. These
cost savings result from sharing information, expertise, and personnel (Lewis, 1990; Geisler et al., 1990; Geisler, 1995).
If partners' knowledge is related to the HTNF's own knowledge domain, new firms can exploit their more specialized
technological capabilities in ways that maximize their ability to acquire knowledge from upstream alliance partners. As noted,
technological capabilities are an integral part of new firms' absorptive capacity (Leonard-Barton, 1995; Cohen and Levinthal,
1990). This capacity “is largely a function of the firm's level of prior related knowledge” (Cohen and Levinthal, 1990: 128).
Knowledge acquisition from alliance partners becomes easier when the knowledge bases of both organizations are similar (Lane
and Lubatkin, 1998). However, developing high levels of absorptive capacity in the particular knowledge domain of a potential
alliance partner is challenging as the HTNF has to focus its scarce resources on building specialized technological capabilities in
that domain. Themore specialized the new firm's technological capabilities in a given domain, the higher its potential absorptive
capacity in that area. Therefore, if the partner's knowledge domain is related to that of the firm, HTNFs with more specialized
technological capabilities are apt to benefit more from forming learning alliances with universities thanwith firms that have less
specialized technological capabilities. Moreover, when the firm has more specialized technological capabilities and its scientists
have expertise related to the scientific field of the university alliance partner, the HTNF can better comprehend themethods used
and the results achieved by its alliance partner. Higher knowledge domain expertise will also make communication easier,
possibly lowering the need for costly coordination.Fig. 1. Theoretical model.
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formed, more specialized technological capabilities could be beneficial. This is because vertical upstream alliances have risks of
their own, and specialized capabilities can help mitigate these risks. The cultures of universities and business organizations are
often incompatible with respect to secrecy and free exchange of knowledge (Bower, 1992). HTNF scientists usually emphasize
knowledge related to NPD, keeping their knowledge secret and reduce its leakage to competitors. However, university scientists
value generating publications (Dasgupta and David, 1994; Haeussler, 2010a). This discrepancy increases the need for coordination,
possibly raising the overall costs of NPD. Increased costs may lower HTNFs' NPD because fewer resources are allocated directly to
these activities.
In addition, having more specialized technological capabilities can mitigate HTNFs' risk in upstream alliances by reducing
university scientists' incentive to develop knowledge that is publishable but irrelevant for the HTNF's purpose. Independent of
their particular area of specialization, targeting their resources to build specialized technological capabilities allows HTNFs'
scientists to work at the scientific frontier and perform cutting-edge research. Possession of in-depth knowledge can facilitate the
effective exchange of information between HTNFs and universities (Hicks, 1995) even if the knowledge domains of both partners
are unrelated. For example, when firm scientists know about recent scientific breakthroughs and the advancement of the field in
general, this can help in the development of a common language with scientists of the university alliance partner and promote the
exchange of ideas and develop mutual respect that fosters joint discovery. In their discussions with university scientists, deep
scientific knowledge can also help firm scientists to judge the significance and future potential of new scientific developments and
signal their competence. When the firm has deep scientific knowledge and understanding of the scientific process, university
partners are less likely to behave opportunistically and pursue their own research interests that lead to publications rather than
NPD because it is more difficult for them to do so without the partner recognizing it.
Further, over the course of the alliance university scientists may develop interest in the HTNF's technology in order to advance
their own research and theymight proceed to build up absorptive capacity in the HTNF's domain and expropriate knowledge from
the HTNF. Themore specialized and sophisticated the HTNF's technology, the better it is protected from its partner's opportunism.
Thus, technological specialization can protect HTNFs, at least to some extent, against opportunistic behavior of upstream alliance
partners irrespective of the HTNF's particular field of specialization. Therefore:
H1. The relationship between the number of vertical upstream alliances and product development is more positive when the
internal technological capabilities of the high technology new firm are more specialized than when they are less specialized.3.2. Technological capabilities and horizontal alliances
Horizontal alliances are established when HTNFs collaborate with other organizations at the same level of the value chain
(Perry et al., 2004). These alliances enable HTNFs to reduce demand uncertainty, achieve and retain strategic flexibility, give
customers a wider range of services, and explore growth opportunities (Burgers et al., 1993; Smith and Barclay, 1997). In turn, this
allows HTNFs to develop new products by accessing their partners' knowledge in design, prototyping, testing, development, and
commercialization (George et al., 2001).
Still, horizontal alliances entail a particularly high risk of failure because alliance partners at the same level of the value chain
are often rivals (Gnyawali et al., 2006; Hamel et al., 1989). These alliances are not pure collaboration agreements; rather, they are
mechanisms for “co-opetition” — a simultaneous cooperation and competition between partners (Brandenburger and Nalebuff,
1996). Though co-opetition can enhance firm performance (Lado et al., 1997), the competition between partners often becomes
more prevalent than cooperation over the course of such an alliance (Khanna et al., 1998; Gnyawali and Madhavan, 2001). For
example, Park and Russo (1996) have found that horizontal alliances in the electronics industry frequently fail because of rising
competition among partners; this competition makes these alliances unstable (Mowery et al., 1996). The combination of the two
fundamentally different logics of cooperation and competition (Bengtsson and Kock, 2000) makes risk sharing among partners or
enforcing contracts to counter moral hazard problems challenging (Tapon, 1989; Deeds and Hill, 1998). The outcomes of the
exploration activities that motivate horizontal R&D alliances are also uncertain and frequently take time to materialize (March,
1991), making it difficult to develop effective contracts that cover the potential outcomes and their successful appropriation by
partners (Carayannis and Alexander, 1999; Deeds and Hill, 1998).
The hypercompetitive environment in which many HTNFs operate often increases the risk of opportunistic partner behavior in
horizontal alliances. Hypercompetition “is a condition of rapidly escalating competition based on price–quality positioning,
competition to create new know-how and establish first-mover advantage, competition to protect or invade established product
or geographic markets, and competition based on deep pockets and the creation of even deeper pocketed alliances” (D'Aveni,
1995: 46). In many high technology sectors a “winner-takes-it-all” scenario exists, andwinning the competition for the creation of
technological knowledge and know-how and its exploitation to gain a first-mover advantage is crucial for HTNFs' success (De
Carolis and Deeds, 1999). Furthermore, in hypercompetitive environments knowledge protection through effective patenting is
essential for HTNFs to limit or delay imitation of their products (Teece, 1986). Under such uncertain, dynamic and hostile
conditions (D'Aveni, 1995) it is difficult for HTNFs to predict how the competitive relationship between the partners will develop
in a co-opetitive, horizontal alliance. Safeguards against these risks are costly, often requiring thorough partner evaluation (Emden
et al., 2006), extensive monitoring, and frequent renegotiation of alliance contracts. These problems can limit the resources the
HTNF has for NPD activities.
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the benefits of horizontal alliances in NPD activities. If the knowledge domains of both partners overlap, efficient learning in
horizontal alliances becomes feasible only when firms have sufficient absorptive capacity to capture, assimilate and apply the new
knowledge created through common R&D efforts (Leonard-Barton, 1995). Competition between co-opeting partners may
encouragemutually opportunistic behaviors that can turn a horizontal alliance into a “learning race” (Grindley andMowery, 1994;
Khanna et al., 1998). Reacting to the partner's learning effort, the HTNF may seek to enrich its own learning and knowledge from
the partner. In turn, this can enhance the partner's motivation to learn. When this happens, partners may use the alliance only to
learn quickly and expropriate asmuch knowledge as possible without being committed to the original good of the alliance. Success
in a learning race, however, requires the HTNF to have specialized technological capabilities and sufficient absorptive capacity to
quickly acquire the partner's knowledge needed for NPD.
Even if the knowledge domains of co-opeting partners do not overlap when the alliance is established, more specialized
technological capabilities can counteract some of the risks arising from their partners' opportunistic behaviors. For example, firms
may enter into alliances to acquire the partner's capabilities through organizational learning. Over the course of the alliance, the
partner may build up knowledge and absorptive capacity in the focal firm's knowledge domain (Khanna et al., 1998). When a
partner is trying to learn, the result may be a “competition for competence” (Hamel, 1991). Specialized technological capabilities
based on highly sophisticated scientific techniques make it difficult for the partner to acquire the firm's knowledge and
incorporate it into its own operations. Further, if the firm's scientists are leading experts in their area of specialization, their
sophisticated and often tacit knowledge will be particularly difficult to acquire for co-opeting partners. This is likely to reduce the
risk that partners will imitate the firm's scientific techniques and develop knowledge and absorptive capacity in that particular
knowledge domain (Fig. 1). Therefore:
H2. The relationship between the number of horizontal alliances and product development is more positive when the internal
technological capabilities of the high technology new firm are more specialized than when they are less specialized.
3.3. Technological capabilities and vertical downstream alliances
Vertical downstream alliances are partnerships formed between HTNFs and organizations that operate downstream of their
value chains. In the biotechnology industry, for example, downstream alliance partners usually include large established
pharmaceutical firms (Rothaermel and Deeds, 2004). Allying with an incumbent can enhance the HTNF's legitimacy by signaling
its ability to develop valuable products (Stuart et al., 1999). These alliances help HTNFs to reinforce their market positions by
avoiding costly and hazardous competition with incumbents (Gans and Stern, 2003).
In contrast to vertical upstream and horizontal alliances, acquiring technological knowledge from the alliance partner is
usually not a primary motive for HTNFs to join downstream vertical alliances. HTNFs form downstream alliances to gain access
to the complementary capabilities needed for NPD (Rothaermel and Deeds, 2004), especially the incumbents' legal and
regulatory competence, manufacturing, distribution and marketing capabilities (Cullen and Dibner, 1993). Complementary
capabilities might also include operational or non-technological knowledge of the downstream partner. For example, in the
context of the biopharmaceutical industry this might include knowledge on how to conduct clinical trials, how to establish and
operate large-scale manufacturing facilities for new products, and how to build up distribution channels and prepare for market
entry. These capabilities are often costly to develop and alliances help the firm avoid making duplicative investments that may
not pay off.
To benefit from downstream alliances and expedite NPD, HTNFs must effectively counteract the risk that – usually
substantially larger and more experienced – downstream partners exploit their negotiating power at the expense of the HTNF.
The loss of exploitation rights reduces HTNFs' ability to appropriate rents from new products and limit their ability to introduce
additional product candidates based on IP associated with the jointly developed products. For instance, Lerner and Merges
(1998) found that biotechnology firms which lack financial resources have little bargaining power in negotiating with an
incumbent partner and therefore join alliances even if the majority of the control and product ownership rights are given to the
incumbent. The same problem occurs when external financing is sparse during times of hostile equity markets. Under these
conditions, HTNFsmay have to give awaymuch of their product ownership in exchange for cash they cannot easily access via the
capital market (Lerner et al., 2003). Giving most control and product ownership rights to the incumbent, however, is inefficient
for NPD because the research firm may not have the incentive to contribute to the success of the alliance. Not surprisingly, NPD
alliances negotiated in hostile equity markets giving the incumbent firm significant control rights are more likely to fail (Lerner
et al., 2003). For HTNFs, the loss of exploitation rights associatedwith the joint project and these failed alliances lead to the loss of
the joint product and the resources needed to develop other product candidates, thereby reducing NPD.
Less specialized technological capabilities usually give HTNFs more flexibility and bargaining power in negotiating alliances
and therefore partially escape their partner's excessive control. The HTNFs' bargaining power increases with the product's
development stage (Aghion and Tirole, 1994) and advancing the product candidate along the value chain requires a more
diverse set of technological capabilities (Henderson, 1993). For instance, NPD in biopharmaceutical firms is a multi-step process
that requires a diversity of competencies in several disciplines (Sorensen and Stuart, 2000; Zhang et al., 2007).When negotiating
alliance terms with a downstream partner, a broader set of technological capabilities will allow HTNFs to reduce asymmetric
information because the HTNFs will have at least some understanding of the technologies used by the downstream partner to
advance the product candidate. This understanding will enable HTNFs to better judge the contribution of the downstream
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product's ownership (Lerner et al., 2003). Overall, as depicted in Fig. 1, HTNFs' less specialized technological capabilities can
strengthen the HTNF's bargaining power and better counteract the risk of over-control in downstream alliances than highly
specialized capabilities. Therefore:
H3. The relationship between the number of vertical downstream alliances and product development is more positive when the
internal technological capabilities of the high technology new firm are less specialized than when they are more specialized.
4. Data, method and analysis
4.1. Data collection and sample
The biopharmaceutical sector provides an optimal setting for our study for several reasons. First, the development of products
and technologies is strongly driven by HTNFs which are responsible for the development of the vast majority of drugs based on
biotechnological methods. Second, due to the resource intensity of the development of biopharmaceuticals, HTNFs in this sector
lackmany of the capabilities and knowledge needed for NPD (Deeds and Hill, 1996). Third, because of HTNFs' resource scarcity, the
building of networks to access collective knowledge is “the” key strategic task for the success of biotechnology and pharmaceutical
firms (Powell et al., 2005; Haeussler, 2010b). Finally, to be successful in the competitive environment faced, entering into alliances
of all three types of our model (upstream, horizontal and downstream) can provide benefits for biopharmaceutical HTNFs (Deeds
and Hill, 1996).
HTNFs in the biopharmaceutical industry usually focus on the early steps of themodern pharmaceutical value chain (Deeds and
Hill, 1996; Rothaermel and Deeds, 2004). The value chain starts with the identification and validation of a target gene or target
protein, the malfunction of which is responsible for the development of a disease. Next, a potential drug candidate which interacts
with the validated target is discovered. In the final part of the research process (the “R” in pharmaceutical R&D) drug candidates
are optimized in a way that the interaction with their target is as strong and as specific as possible. The drug candidate then enters
the development process (the “D” in pharmaceutical R&D) starting with preclinical development. At this step, the drug candidate
is analyzed in animal models and may be optimized again to circumvent undesired side effects. The drug is then tested in three
subsequent clinical phases with healthy volunteers and patients suffering the targeted disease. Ultimately, if test results are
supportive, the drug is approved by the regulatory authorities (DiMasi et al., 2003). HTNFs' role in this process typically includes
the research-related steps, preclinical testing, and the first one or two clinical development steps before downstream alliances
with pharmaceutical incumbents are entered to finalize the last andmost expensive steps of the process and introduce the drug to
the market (Rothaermel and Deeds, 2004).
Testing our hypotheses required measuring the alliance portfolio, technological capabilities and product development by
HTNFs. Given that data on these variables were not available from public sources or commercial databases, we surveyed
biotechnology firms in the UK and Germany, the largest andmost developed biotech industries in Europe (Ernst and Young, 2008).
The target population included all firms active in the biopharmaceutical sector, as defined by OECD (2005). We restricted our
sample to this sector as there are significant differences in the degree of innovativeness, the level of R&D spending, and the
regulatory processes between the human biopharmaceutical sector and other sectors such as agricultural or veterinary
biotechnology (Deeds and Hill, 1996). In identifying companies, we excluded those firms that were not founded in the two
countries, firms that were subsidiaries of foreign firms, and those firms solely offering services or supplying products without
conducting research. Firms were identified from several industry sources (e.g., Biocom, Dechema and Bio Commerce), regional
databases like Erbi and Bio-M and internet searches. We checked the lists of firms targeted in the survey against our selection
criteria with the help of biologists and biotechnologists. The final population consisted of 343 British and 346 German
biotechnology firms. Data were collected in 2006.
Each firm received a personalized letter, addressed to the most senior manager, requesting their participation in the study.
Prior to field data collection, we engaged industry experts from biotechnology associations as well as firms in designing the survey
instrument.We also conducted 12 interviews to pre-test the questionnaire, leading us to revise the phrasing and sequencing of the
questions. We conducted face-to-face interviews because biotechnology firmmanagers preferred this to mail and on-line surveys.
Interviews also allowed us to clarify issues and better understand the choices HTNFs made. Interviews were conducted with 118
British and 162 German firms which agreed to participate in our study. This response rate of 47% for Germany and 34% for the UK
provided us with a comprehensive sample of British and German biotechnology firms.
The “structured” interviews lasted approximately 35 min and were based on a preformatted questionnaire. Interviewers read
the questions exactly as they appeared on the survey questionnaire and filled in the answers. The choice of answers to the question
was mostly fixed (close-ended) in advance with the possibility to comment. Given that this study is designed to address issues of
major strategic importance, we conducted the interviews with high-level managers. Eighty-nine percent of German interviews
and 96% of British interviews were conducted with executive level interviewees. Furthermore, 73% and 65% of the German and
British interviews respectively were conducted with the CEO/General Manager of the firm. The average interviewee had been
working for the company for 6.5 years (UK) and 5.2 years (Germany).
Given our focus on NPD, we included only those firms that were active in the development of biopharmaceutical products. We
therefore excluded 67 firmswhichwere either not developing therapeutic, vaccine or diagnostic products or were solely providing
contract research. Thus, firms developing platform technologies are not included in the sample. We chose these fields of activity
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capabilities (George et al., 2001; De Carolis and Deeds, 1999; Shan et al., 1994; Zahra, 1996). Furthermore, 14 observations have
been excluded because of missing variables. The final sample included 82 British and 117 German firms that are involved in NPD
and provided the data requested. We pooled both samples because our testing for homogeneity of variance did not indicate
significant country differences in NPD.4 Our final sample consisted of 199 firms.
4.2. Dependent variable
The study's dependent variable is a firm's new product development. Previous research highlights the long development time
for biotechnological products, leading to only a few products having reached the market (e.g., Shan et al., 1994; Deeds and Hill,
1996; Deeds et al., 1999). Prior studies also suggest that an appropriate measure of the innovative output of biotechnology firms
should consider products that are in regulatory trials and targeted to reach the market at some future date. Thus, our measure
includes products on the market and products currently under development. Still, given our focus on relating alliance type and
the degree of specialization of technological capabilities to the firm's innovativeness (not the success of acquiring products
developed externally), we excluded products that have been licensed in, have been bought, or have entered the firm's product
pipeline via take-over of another firm. Yet, including externally developed products in our measure would have increased the
likelihood that alliances are developed solely to acquire those product candidates. This would have made the alliance a count
variable (the “independent variable”) measure being partly the same as the dependent variable. Thus, our dependent variable is
operationalized as the sum of all internally developed products (i.e., therapeutics, vaccines and diagnostics) in a firm's pipeline
that have successfully entered the preclinical and/or clinical stage as well as those products that have already entered the
market.5 We obtained this variable from our survey of biotechnology managers.
4.3. Independent variables
Following our theoretical framework and Fig. 1, three variables capture a firm's alliance portfolio. Upstream alliances is a count
variable of a firm's upstream vertical alliances with universities or publicly financed research organizations, those which focus on
upstream activities of the value chain. Horizontal alliances is also a count variable of a firm's alliances with other biotechnology
firms. Downstream alliances is a count variable of a firm's downstream vertical alliances with pharmaceutical firms.
The survey defined an alliance as thefirm's active participation in joint projects. This definition excluded pure commissioning.
To ensure accuracy,we asked interviewees to provide the number of formal and informal co-operative projects.6 Thus, we did not
restrict the analysis to formal alliances because we did not know the extent to which formal alliances were more or less
productive when compared to informal ones. Some prior research has shown that informal collaboration is important for a firm's
innovativeness (e.g., von Hippel, 1987; Schrader, 1991).
Technological capabilities refer to the technical specialization of firms. We captured this variable by counting the number of
biotechnological techniques a firm is able to use in the development of its products. A firm is often built around specific technical
capabilities. Our measure thus reflects the technical capabilities at the outset of a firm. Consequently, we differentiated between
DNA/RNA based on techniques, proteins and molecules, cell tissue culture and engineering as well as subcell techniques, process
techniques, bioinformatics, and nanobiotechnology. These are the main areas of biotechnological techniques used in practice
(OECD, 2005). We asked our interviewees which capability their firm uses and when it was built internally. Our use of the number
of different “types” of technological capabilities is consistent with prior research (Mayer and Salomon, 2006).
4.4. Control variables
Our analyses also included the following variables as control variables because they could influence the firm's number of new
products.
We controlled for the business model firms pursue. In biotechnology, a common strategy of young firms is to follow a dual
business model. These firms offer contract research or services to third parties in order to finance their own R&D activities. This
“boot-strapping approach”may impede the rapid development of products (Haagen et al., 2007). We therefore included a dummy
variable indicating whether a firm pursues such a dual business model or not.
Likewise, we controlled for firm age because older firms may have more products in development and on the market than
younger firms (Deeds and Hill, 1996; Rothaermel and Deeds, 2004). We measured firm age by the log of the days from a firm's
inception to December 31, 2005.4 We performed three tests for the equality of variances between British and German firms in NPD. The Levene test (p=0.49) as well as Brown and Forsythe
tests replacing the mean in Levene's formula with the median (p=0.93) and with the 10% trimmed mean (p=0.90) were not significant and thus suggested tha
both samples could be pooled.
5 We asked our interviewees to provide us with the number of products/technologies in the different development stages and products on the market tha
“have been developed internally.”
6 The exact wording of the question is “how many formal and informal co-operative projects is your company currently involved in with the following
partners?” A) with universities and specialist research institutions, B) with other biotechnology firms and C) with pharmaceutical firms. We further note tha
“[w]e define co-operation as active participation in joint projects with other companies or non-commercial organizations. […] [P]ure commissioning is no
defined as co-operation.”'
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have received this type of capital might have more products in the pipeline and on the market as compared to non-VC financed
firms because they are likely to profit from services provided by their investors (Sapienza, 1992) and may have more money to
support R&D. Further, previous studies report the heterogeneous impact of being either VC financed or not. Some studies have
shown that VC funded firms have a higher cash flow and sales growth (e.g., Jain and Kini, 1995). However, other studies do not find
any significant effect of VC financing on firms' sales and employment growth (e.g., Buergel et al., 2002).
The analyses also controlled for the effect of R&D intensity on NPD, using the number of R&D employees. Researchers have
examined the relationship between R&D intensity and productivity (e.g., Pakes, 1985; Grabowski and Vernon, 1990). The most
prominent measure for R&D intensity is R&D expenditures divided by company sales. However, because they are in their early
development stage, many biotechnology firms do not have a positive revenue stream. Also, when they do, the revenue often comes
from offering services, and not from the sale of their products (Haagen et al., 2007). Therefore, we use the log of the number of
employees working in R&D (i.e., chief scientific officer, researchers and developers, and technicians) as a proxy for R&D intensity.
The study also controlled for the sector in which firms operate by including the dummy variable therapeutics in the analyses.
Firms developing therapeutics are likely to have fewer products in development or on the market than firms developing
diagnostics. Introducing a therapeutic drug to the market usually takes much longer and is more costly than introducing a
diagnostic product.
The analyses controlled for firm location by using a dummy variable German firm to indicate whether the firm is located in
Germany or in the UK. Though the literature on national innovation systems does not indicate country differences in the effects of
alliance types or technological capabilities on NPD, to be conservative, we included this variable to account for potential
differences. Table 1 summarizes the variables and the measures and related items from the interview questionnaire.
5. Results
5.1. Descriptive statistics and correlations
Table 2 reports the descriptive statistics for, and the correlations among, the study's variables. The average firm in the sample
had 3.8 products in development or on the market, had entered into 4.1 vertical upstream alliances, 3.9 horizontal alliances, 2.2
vertical downstream alliances, and was able to use 2.5 biotechnological techniques. The average firm was also 8.2 years old
(median: 6.1 years) and, on average, had 33 employees working in R&D (median: 12). Forty-six percent of the firms were VC
financed, 61% develop therapeutic drugs, 59% of the sample was German, and 59% pursued a dual business model.
Further, Table 2 indicates moderate to high correlations between the different types of alliances ranging from 0.53 (upstream–
downstream) to 0.72 (horizontal–downstream). This finding, however, is consistent with many other studies on alliances. For
example, in their study of 132 biotechnology firms, Deeds and Hill (1996) report a correlation of 0.63 between the number of
alliances with other biotechnology firms and pharmaceutical firms. Similarly, George et al. (2001) find a correlation of 0.75Table 1
Variables and measures.
Variables Measures in the survey Type of variable
Count variable Dummy variable
Dependent variable
Number of products Products on the market and currently under development
(subtracting number of in-licensed and acquired products as well
as products acquired through take-over of another firm).
X
Independent variables
Upstream alliances Number of alliances with universities or publicly financed
research organizations.
X
Horizontal alliances Number of alliances with other biotechnology firms. X
Downstream alliances Number of alliances with pharmaceutical firms. X
Technological capabilities Number of biotechnological techniques the firm is able to use out of
the following: DNA/RNA based technique, proteins and molecules,
cell tissue culture and engineering, subcell techniques, process techniques,
bioinformatics, nanobiotechnology. [Note: The date since the technique is
available in-house is taken into account].
X
Control variables
Dual business model =1, when the firm pursues a dual business model (offers contract
research or services to finance own R&D activities), 0 otherwise.
X
Log Age Logarithmic form of the days from a firm's inception to December 31, 2005. X
Vcfinanced =1, when the firm received VC financing, 0 otherwise. X
Log(R&D employees) Logarithmic form of the number of employees in R&D. X
Therapeutics firm =1, when the firm develops therapeutics or vaccines, 0 otherwise. X
German firm =1, when the firm is located in Germany, 0 otherwise X
Table 2
Descriptive statistics and correlations.
Variables Mean S.D. 1 2 3 4 5 6 7 8 9 10
1. Number of products 3.82 5.64 1
2. Technological capabilities 2.54 1.52 −0.08 1
3. Upstream alliances 4.07 7.46 0.08 0.22 1
4. Horizontal alliances 3.88 8.72 0.05 0.13 0.65 1
5. Downstream alliances 2.22 5.66 0.06 0.17 0.53 0.72 1
6. German Firm 0.59 n.a. 0.09♦ −0.14♦ 0.21♦ −0.06♦ −0.05♦ 1
7. Log(age in days) 7.78 0.65 0.26 −0.01 0.1 0.26 0.23 −0.09♦ 1
8. VCfinanced 0.46 n.a. 0.12♦ 0.23♦ 0.10♦ 0.10♦ 0.15♦ −0.04◊ 0.09♦ 1
9. Log(R&D employees) 2.69 1.09 0.1 0.34 0.34 0.32 0.39 0.03♦ 0.38 0.31♦ 1
10. Therapeutics firm 0.51 n.a. −0.07♦ 0.10♦ 0.12♦ 0.06♦ 0.20♦ 0.07◊ −0.13♦ 0.09◊ −0.02♦ 1
11. Dual business model 0.59 n.a. −0.07♦ −0.001♦ 0.08♦ 0.08♦ 0.13♦ 0.04◊ −0.09♦ −0.06◊ 0.005♦ −0.12◊
Note: Pearson product moment correlation unless otherwise stated; ◊ Cramers' V; ♦ Spearman rank correlation coefficient. N=199.
7 Furthermore, a discriminant analysis extracted two dimensions of alliance activities for NPD. The first significant dimension reflects a horizontal versus
vertical dimension while the second is an upstream versus downstream dimension. These results provide further justification for our distinction among
upstream, vertical and downstream alliances.
226 C. Haeussler et al. / Journal of Business Venturing 27 (2012) 217–233between the number of horizontal and vertical alliances in their study of 143 biotechnology firms. Studying 352 biotechnology
firms Rothaermel and Deeds (2004) report a correlation of 0.52 between exploration (upstream) and exploitation (downstream)
alliances. McKelvey (1996) explains this observation arguing that the economics of biotechnology are either a small-firm
phenomenon or a complex division of labor along the value chain, where firms co-specialize in different parts of the value chain.7
5.2. Poisson regression analysis
Table 3 reports the results on the determinants of the number of products on the market and products currently under
development. The preponderance of small values and discrete nature of the dependent variable suggests using a log linear Poisson
model. Poisson probabilities are widely used tomodel the number of occurrences of an event (Greene, 2003; Cameron and Trivedi,
1998). We first entered the variable indicating the technological capabilities of a firm and the control variables (Model M1). Next,
we added the three variables capturing the number of upstream, horizontal and downstream alliances, respectively, and their
interactions with the technological capabilities variable (M2–M7). Model 8 contains all alliance variables but no interactions. In
Models M9–M11 we add interactions of upstream, horizontal, and downstream alliances, respectively. Model M12 includes all
three alliance variables and all interaction terms.
Models in Table 3 indicate that the sign and significance of the interaction variables are robust across the Poisson models.
Specifically, there is a negative and significant interaction between upstream alliances and technological capabilities in models M3
(coefficient=−0.012, pb0.01) and M9 (coefficient=−0.008, pb0.05). The interaction is also significant in the full model M12,
albeit only marginally (coefficient=−0.007, pb0.10). This provides some support for Hypothesis H1 positing that the
relationship between upstream alliances and NPD is more positive when the number of technological capabilities decreases (i.e.,
their specialization increases).
There is a negative interaction between horizontal alliances and technological capabilities. This interaction is non-significant
in M5, but it becomes significant in M10 (coefficient=−0.010, pb0.01) and highly significant in the full model (M12:
coefficient=−0.017, pb0.001). This interaction indicates that the relationship between horizontal alliances and NPD is more
positive when the number of technological capabilities decreases (i.e., their specialization increases). This supports Hypothesis
H2, depicted in Fig. 1. There is also a positive and highly significant interaction between downstream alliances and technological
capabilities in all models (M7: coefficient=0.037, pb0.001; M11: coefficient=0.032, pb0.001; M12: coefficient=0.037,
pb0.001). These results show that the relationship between downstream alliances and NPD ismore positive when the number of
technological capabilities increases (i.e., their specialization decreases), thereby supporting Hypothesis H3 (see Fig. 1).
5.3. Robustness checks and endogeneity
We conducted additional tests to establish the robustness of the results we have just presented. In conducting these tests, we
considered the issue of endogeneity in our model especially regarding the firm's technological capabilities and strategic alliances.
It is possible that a HTNF's alliances trigger or enhance the development of technological capabilities (e.g., if the knowledge
acquired in the alliances leads to the development of scientific techniques, the foundation of technological capabilities in our
study). These capabilitiesmay improve the firm's rate of product development. To address this issue and test whether our results
are driven by the proposed mechanism, we made use of the fact that our data set lists the date when the firm has built a specific
technological capability. This allows us to identify those capabilities which the firm possessed at the time it was founded. While
path dependency arguments would suggest that these capabilities are highly influential for the future technological path of the
firm (Teece et al., 1997), they are exogenous to our model. If we calculate the full model with these initial technological
Table 3
Results of Poisson model. Dependent variable: number of products; estimation method: Poisson; IV designates an instrumented model.
Coefficient M1 M2 M3 M4 M5 M6 M7 M8 M9 M10 M11 M12 M13 TCs at
founding
M14 IV
Technological
capabilities
−0.091** −0.0955*** −0.062* −0.090** −0.096** −0.092** −0.161*** −0.117*** −0.092** −0.097** −0.169*** −0.124*** −0.069+ −0.172**
(0.028) (0.029) (0.031) (0.028) (0.030) (0.028) (0.031) (0.029) (0.031) (0.030) (0.031) (0.033) (0.038) (0.060)
Upstream alliances 0.006 0.051** 0.029*** 0.058*** 0.039*** 0.025*** 0.067*** 0.067*** −0.109**
(0.004) (0.017) (0.007) (0.015) (0.007) (0.007) (0.015) (0.011) (0.037)
Upstream alliances x −0.012** −0.008* −0.007+ −0.018** −0.014
Technological
capabilities
(0.004) (0.004) (0.004) (0.006) (0.013)
Horizontal alliances −0.007* −0.014 −0.038*** −0.037*** −0.013 −0.024** 0.027+ 0.008 0.175*
(0.004) (0.011) (0.007) (0.007) (0.011) (0.007) (0.014) (0.013) (0.071)
Horizontal alliances x 0.002 −0.010** −0.017*** −0.019* −0.080***
Technological
capabilities
(0.003) (0.004) (0.004) (0.008) (0.016)
Downstream alliances 0.003 −0.142*** 0.026** 0.026** 0.030*** −0.116** −0.136*** −0.115*** −0.311*
(0.006) (0.029) (0.009) (0.009) (0.009) (0.037) (0.035) (0.020) (0.135)
Downstream alliances x 0.037*** 0.032*** 0.037*** 0.051*** 0.184***
Technological
capabilities
(0.007) (0.008) (0.007) (0.007) (0.027)
Dual Business Model −0.230** −0.222** −0.237** −0.241** −0.235** −0.230** −0.166* −0.256*** −0.259*** −0.288*** −0.200** −0.215** −0.300*** −0.179*
(0.074) (0.074) (0.075) (0.074) (0.075) (0.074) (0.075) (0.075) (0.075) (0.076) (0.076) (0.077) (0.077) (0.078)
Log Age 0.541*** 0.538*** 0.554*** 0.560*** 0.566*** 0.538*** 0.538*** 0.591*** 0.600*** 0.574*** 0.567*** 0.536*** 0.495*** 0.424***
(0.062) (0.062) (0.063) (0.063) (0.063) (0.062) (0.063) (0.063) (0.063) (0.063) (0.063) (0.065) (0.065) (0.084)
Vcfinanced −0.088 −0.099 −0.092 −0.070 −0.070 −0.089 −0.066 −0.049 −0.050 −0.039 −0.044 −0.050 −0.196* −0.155
(0.078) (0.078) (0.079) (0.078) (0.078) (0.078) (0.079) (0.079) (0.079) (0.079) (0.079) (0.079) (0.080) (0.124)
Log(R&D employees) 0.068+ 0.047 0.051 0.095* 0.091* 0.060 0.072+ 0.052 0.052 0.057 0.061 0.079 0.086* 0.307*
(0.037) (0.040) (0.040) (0.039) (0.040) (0.041) (0.041) (0.041) (0.041) (0.041) (0.041) (0.041) (0.040) (0.141)
Therapeutics firm −0.663*** −0.649*** −0.662*** −0.679*** −0.670*** −0.664*** −0.608*** −0.728*** −0.725*** −0.782*** −0.652*** −0.699*** −0.634*** −0.482*
(0.077) (0.077) (0.078) (0.077) (0.079) (0.077) (0.077) (0.080) (0.080) (0.083) (0.082) (0.084) (0.082) (0.216)
German firm 0.180* 0.149+ 0.110 0.190* 0.181* 0.178* 0.187* 0.080 0.048 0.084 0.110 0.081 0.049 0.514***
(0.077) (0.081) (0.082) (0.077) (0.078) (0.077) (0.078) (0.080) (0.083) (0.081) (0.081) (0.085) (0.084) (0.124)
Constant −2.520*** −2.441*** −2.665*** −2.715*** −2.738*** −2.477*** −2.389*** −2.758*** −2.896*** −2.690*** −2.530*** −2.482*** −2.226*** −2.212***
(0.507) (0.511) (0.522) (0.514) (0.515) (0.515) (0.519) (0.512) (0.520) (0.514) (0.518) (0.530) (0.532) (0.651)
Observations 199 199 199 199 199 199 199 199 199 199 199 199 199 199
Pseudo Rsquared 0.157 0.158 0.162 0.159 0.159 0.157 0.182 0.176 0.179 0.180 0.190 0.204 0.21 0.213
chi2 260.0 261.8 269.0 264.1 264.5 260.2 301.2 292.7 297.0 299.3 315.3 338.0 348.8 353
ll −699.4 −698.5 −694.9 −697.3 −697.1 −699.3 −678.8 −683.1 −680.9 −679.8 −671.8 −660.4 −655 −652.9
Standard errors in parentheses, ***pb0.001, **pb0.01, *pb0.05, +pb0.1. The IV model (M14) represents only the second stage model. The first results are available from the authors upon request.
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228 C. Haeussler et al. / Journal of Business Venturing 27 (2012) 217–233capabilities instead of the capabilities the firm had at the time of our field work, we find that the results change little (compare
models M12 andM13 in Table 3). Specifically, the interaction between upstream alliances and initial technological capabilities is
negative and significant (coefficient=−0.018, pb0.01). Moreover, the interaction between horizontal alliances and initial
technological capabilities is significant and negative (coefficient=−0.019, pb0.05). The interaction between upstream
alliances and initial technological capabilities is positive and significant (coefficient=0.051, pb0.001). This indicates that
endogeneity of technological capabilities is not a serious problem in the analyses we reported earlier in this paper.
Some previous studies highlight the endogenous character of firms' alliances (e.g., Gulati, 1998). For instance, the technological
capabilities of a firm may drive its alliances, which in turn impact its NPD. Alternatively, high rates of NPD may make a HTNF an
attractive alliance partner and thus influence its alliance formation. To address the endogenous character of upstream, horizontal,
and downstream alliances, we use a count-data instrumental variables model developed by Mullahy (1997). This model is a
generalized method of moments (GMM) model for count data with endogenous variables — an instrumented Poisson model.
Angrist (2001) shows that this model provides consistent estimates. In conducting our analyses, we use four exogenous variables
as instruments for the number of alliances variables.
We use three variables representing the level of incoming knowledge flows from external sources of information to indicate the
exogenous available spillover pool (Cassiman and Veugelers, 2002). In the survey, we asked our interviewees to what extent three
external sources of information are important for their R&D activity on a five-point Likert scale ranging from not important (1) to
extremely important (5). The external sources of information are a) universities (upstream alliance partners), b) customers
including collaborating customers (downstream alliance partners) and c) competitors in the same field of activity (horizontal
alliance partners). On average, our interviewees rate universities as important sources of information for R&D (mean: 3.9); thiswas
higher than customers (3.7) and competing firms (3.0) as sources of information. Furthermore, as a fourth instrumental variable,
we use a dummyvariable indicatingwhether the firm is a spin-out of a university or a research institute. The R&Dof these spin-outs
is more likely related to basic research than the R&D of other firms. Cohen and Levinthal (1990) argue that the type of R&D
influences the firm's capacity for profiting from external knowledge (as knowledge gained through alliances). Since both our
models pass the Sargan (p=0.49) and the Basman (p=0.51) test of overidentification, it appears that there is sufficient validity of
our instruments.
Model 14 in Table 3 presents the results, taking the endogeneity of alliance variables into account. Comparing the coefficients of
our interaction variables in the full un-instrumented model (M12) with the instrumented model (M14), we find that the
interaction between upstream alliances and technological capabilities is still negative, but its significance diminishes
(coefficient=−0.014, pN0.1). This indicates that the weak support for H1 is not robust when we take endogeneity of upstream
alliance variables into account. The interaction between horizontal alliances and technological capabilities also is negative and
highly significant (coefficient=−0.080, pb0.001), providing additional support for H2 from the instrumented model. The
interaction between downstream alliance and technological capabilities is positive and highly significant (coefficient=0.184,
pb0.001), indicating that support for H3 is also robust. Finally, the sign and significance of the other control variables remain to a
large extent robust in the instrumented model.
Overall, our robustness tests of endogeneity suggest that our basic premise holds, although the interaction related to H1 shows
the same sign but is not significant in the instrumented Poisson model. Clearly, the results support the study's three hypotheses,
but support for H1 is weak.
6. Discussion
A large body of research has focused on the role of strategic alliances in giving partnering firms superior value relative to
alternative organizational forms, even though alliances are frequently prone to failure (Madhok and Tallman, 1998). One of the
key areas where alliance members often benefit is NPD (Rothaermel and Deeds, 2004), a major source of revenue and growth
(Baum et al., 2000). However, NPD is risky because firms do not always have the requisite internal capabilities and frequently have
to obtain them from external sources such as alliances. In this paper, we have proposed that different types of alliances give the
firm differential access to different types of capabilities (Rothaermel and Deeds, 2006). This is especially the case among HTNFs
that often do not have the resources and experiences to build the right mix of capabilities they need on their own. Applying the
capabilities perspective, we have explored how upstream, downstream and horizontal alliances impact HTNFs where NPD is
essential to these firms' survival, growth and profitability. Building on the capabilities perspective, we have also proposed that this
effect depends on the degree of specialization of HTNFs' internal technological capabilities. Table 4 summarizes how our results
compare to previous studies, which we discuss next.
Our research underscores the importance of internal technological capabilities in determining HTNFs' potential benefits and
risks when they join strategic alliances. The results extend the literature showing that alliance success depends on a firm's alliance
experience (Hoang and Rothaermel, 2005) and the munificence of its financing environment (Lerner et al., 2003). Rothaermel and
Deeds (2006) have also shown that young biotechnology firms with considerable alliance experience stand to gain more benefits
from entering into additional alliances (up to a certain point) than firms with more limited experience. Our study focuses on
HTNFs' internal technological capabilities and shows that the degree of specialization of these capabilities significantly influences
the contribution of strategic alliances to their NPD.
Most prior research has examined individual alliances' level of analysis, showing that alliances fail because of opportunistic
partner behavior (Deeds and Hill, 1998) and misallocation of control rights (Lerner et al., 2003). However, prior studies have
neglected the effect of alliance failure on organizational performance. At the organizational level some studies have argued that,
8 Several factors might have contributed to these differences. Specifically, in our research the dependent variable considers only products that have been
developed internally by the firm. We have also gathered alliance data by administering a survey which allows us to take formal and informal alliances into
account, whereas the studies cited used only formal alliances as reported in the Bioscan database. In addition, our sample consists of German and UK
biotechnology firms whereas firms listed in Bioscan are mainly US-based.
Table 4
Summary comparison between this study's and previous work on alliances.
Previous studies This study
Extending Supporting Contradicting
Alliances in general
(Hoang and Rothaermel, 2005) X
(Lerner et al., 2003) X
(Deeds and Hill, 1996) X
(Rothaermel and Deeds, 2006) X
Upstream vertical alliances
(Rothaermel and Deeds, 2006) X X
(Zucker et al., 2002) X
(Oliver and Liebeskind, 1998) X
(Powell et al., 1996) X
(Owen-Smith and Powell, 2004) X
(George et al., 2001) X X
Horizontal alliances
(Rothaermel and Deeds, 2006) X X
(Baum et al., 2000) X (X)
Deeds and Hill (1999) X X
(Mowery et al., 1996) X
(Park and Russo, 1996) X
(Khanna et al., 1998) X
(Gnyawali and Madhavan, 2001) X
Downstream vertical alliances
(Rothaermel and Deeds, 2006) X X
(Gulati and Higgins, 2003) X (X)
(George et al., 2001) X (X)
(Lerner and Merges, 1998) (X)
(Lerner et al., 2003) (X)
Note: (X) indicates partial support.
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adding a new alliance, finding curvilinear relationships between either the total number of alliances (Deeds and Hill, 1996) or the
number of upstream, horizontal, and vertical alliances (Rothaermel and Deeds, 2006) and NPD. Thus, HTNFs may not have
sufficient financial and managerial resources to manage the complexity of a large alliance portfolio, leading to diminishing and
finally negative returns from joining new alliances. Though we have tested for curvilinear relationships, we found limited support
only in the case of horizontal alliances. The significance of this effect disappeared after interaction effects were considered.8
Whenwe consider the interaction effects of technological capabilities with individual types of alliances, our results challenge
some previous findings in the biotechnology industry. For instance, with respect to upstream alliances, several prior studies have
emphasized the benefits of upstream alliances for HTNFs (Zucker et al., 2002; Rothaermel and Deeds, 2006; Oliver and
Liebeskind, 1998; Powell et al., 1996; Owen-Smith and Powell, 2004). This is consistentwith our finding that there is a significant
and positive main effect for the number of upstream alliances on NPD in most models of our regression analysis (as reported in
Table 3, models M3, M8, M9, M10, M11, M12, and M13). Interestingly, however, George et al. (2002) report that new
biotechnology firms that have links with universities do not developmore products than firmswithout these linkages. Our study
suggests one potential reason for this finding — the effect of university linkages on NPD depends on the specialization of the
HTNF's technological capabilities. Hence, only when technological capabilities are specialized and the HTNF has a deep
understanding of the university's research, it will have enough absorptive capacity to capitalize on the scientific knowledge
created by its alliance partner. Otherwise, the HTNF may be unable to integrate this knowledge and effectively monitor its
partner's R&D activities leaving it vulnerable to the risk of opportunistic behavior (Bower, 1992). Even if knowledge domains of
alliance partners do not overlap and the HTNF's primary alliance objective is not the acquisition of new knowledge but only
accessing the partner's technology, reputation in the scientific community based on technological specialization (Hicks, 1995)
may protect HTNFs from upstream partners' opportunism. Clearly, analyzing these interaction terms is necessary to better
understand the effect of university alliances on a firm's NPD.
The results also indicate that horizontal alliances and co-opetition may not necessarily be as hazardous as sometimes
assumed in the literature. For example, Baum et al. (2000) found a negative effect of horizontal alliances on biotechnology firms'
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because competition among alliance partners may becomemore prevalent than cooperation (e.g., Deeds and Hill, 1999; Mowery
et al., 1996; Park and Russo, 1996; Khanna et al., 1998; Gnyawali and Madhavan, 2001). Supporting these arguments, we find a
negative and significant main effect of the number of horizontal alliances on NPD in models where interactions between
technological capabilities and horizontal alliances are excluded (Table 3,modelsM4,M8,M9, andM11). Still, the picture changes
whenwe consider interaction terms: the negativemain effect relationship becomes either non-significant (modelsM5,M10, and
M13) or even (marginally) significant and positive (models M12 and M14).
It appears that for HTNFs a more specialized capability base mitigates the risks and/or enhances the upside potential of
horizontal alliances in a way that makes these alliances more beneficial for NPD. Consistent with the literature on co-opetition
(Brandenburger and Nalebuff, 1996), when the firm's scientific reputation is tied to technological specialization, it allows for a
better negotiation of alliance contracts and protects from partners' opportunism. Alternatively, specialization based on highly
sophisticated technologies may protect the HTNF's knowledge base from partner's expropriation efforts, a key to success in co-
opetitive alliances (Hamel et al., 1989; Khanna et al., 1998). Considering interactions between a HTNF's technology base and its
horizontal alliances appears necessary to better appreciate the effect of co-opetition on NPD.
Some scholars have also highlighted the beneficial effect of vertical downstream alliances on new firms' products on the
market (George et al., 2001). One exception is the work by Lerner and colleagues (Lerner and Merges, 1998; Lerner et al., 2003),
who identified cash constraints and hostile financing environments as potentially pressuring biotechnology firms to join
downstream alliances under unfavorable conditions and even give away much of their products' future. Gulati and Higgins
(2003) found no relationship between downstream alliances and a successful Initial Public Offering (IPO) among new
biotechnology firms. Thus, existing literature is unclear of whether downstream alliances are overall beneficial for HTNFs or not.
Our findings highlight the complexity of downstream alliances' contribution to firm performance. For example, consistent
with Gulati and Higgins (2003), we do not find a main effect of downstream alliances on NPD in Model M5. However, consistent
with George et al. (2001), we find a significant and positive relationship between downstream alliances and NPD inmostmodels
where only the main effect is considered (models M8, M9, and M10). Yet, introducing the interaction term between
technological capabilities and downstream alliances provides a more detailed and accurate picture of the relationships at hand.
In thesemodels, themain effect is significant and negative, while interaction terms are significant and positive. This suggests that
the contribution of downstream alliances to NPD is contingent on the firm's technological specialization. Thus, only a subset of
biotechnologyfirms (i.e., thosewith less specialized technological capabilities) benefit from this type of alliance in their NPD and,
perhaps, subsequent IPO valuation. For HTNFs with more specialized technological capabilities, downstream alliances are not as
beneficial (or even detrimental — see Lerner and Merges, 1998; Lerner et al., 2003) to NPD.
Our results are best interpreted in the broader context of the capabilities-based view of alliance formation. As noted, this
perspective emphasizes that firms enter into alliances to gain access to the complementary capabilities of partners (Das and
Teng, 2000; Gomes-Casseres, 1996). Complementarity refers to the distinctive competencies of both partners (Hill and
Hellriegel, 1994). Our study supports this perspective by showing that having the appropriate internal capabilities is a
prerequisite for capitalizing on a partner's capabilities. When internal technological capabilities are not sufficiently specialized,
the HTNF may fail to profit from knowledge capabilities of upstream and horizontal alliance partners. In contrast, when
capabilities are too specialized, accessingmanufacturing andmarketing capabilities through downstream alliances may depress
rather than enhance the firm's NPD efforts.
6.1. Implications for managerial practice
HTNFs are often established to exploit opportunities by developing and introducing new products to markets. Given the
limitations of their skills and experiences, these firms often join alliances — sometimes even under unfavorable conditions. Our
results highlight the importance of HTNFs recognizing the risks associated with strategic alliances. Driven to develop and
commercialize new products, reduce costs and shorten the NPD cycle, new firm managers sometimes overlook these risks and
join alliances that do not give them a competitive advantage. Partners are often attracted to HTNFs because of their
inventiveness in creating products that could change the industry and rules of competition. Our results indicate that HTNFs'
managers should consider their own technological capabilities when considering an alliance partner. In particular, the
specialization of HTNFs' technological capabilities can significantly influence their ability to acquire or access additional
capabilities from external sources. These capabilities have differential effects with different types of alliances. Thus, matching
new firms' technological capabilities (especially their specialization) with the types of alliances they join can influence their
knowledge and other types of gains.
6.2. Limitations and future research
This study's findings should be interpreted with its limitations in mind. For instance, the results draw attention to the
importance of the breadth versus depth of the degree of a firm's technological specialization, an issue not explored in this study.
Future researcherswould benefit fromdeterminingwhether breadth and depth have different effects onNPD. It is also important
to establish if HTNFs can have a variety of technological capabilities and still excel in all these capabilities. This will help improve
our appreciation of the importance of the diversity of technological capabilities for the survival, success, growth and the
evolution of high technology new firms. Researchers need also to explore how the scope of these firms' technological capabilities
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examine the implications of having these technological and other capabilities (e.g., alliance capabilities) for building HTNFs'
knowledge base (and hence absorptive capacity).
Our results are also derived from the biotechnology sector, a prominent example of science intense and collaborative industry.
Biotechnology firms usually have to cover the gamut of activities that occur between invention and commercialization,
necessitating a large number of alliances especially in the downstream portion of their value chain. Given that this increasing
number of cooperative relationships is also common in other industries (Arora et al., 2001), future research should validate our
findings in other industries.
7. Conclusion
New firms in high technology industries have used alliances to gain the knowledge and other resources necessary for successful
NPD. Despite their benefits, alliances pose significant risks for HTNFs. This study draws on the capabilities perspective of alliance
formation and a survey of 199 biotechnology firms from Germany and the UK to investigate how alliance patterns influence NPD.
We find that the specialization of new firms' technological capabilities can help managers use alliances more productively when it
comes to NPD. Our results are stable over a variety of different model specifications and when we account for the endogeneity of
alliances. The analyses reveal differential effects for upstream, horizontal, and downstream alliances. For those alliances where the
acquisition and generation of knowledge is a key goal for HTNFs (i.e., upstream and horizontal), specialized technological
capabilities appear to be a prerequisite for developing the absorptive capacity needed to capture and commercially exploit this
knowledge. Even if a partner's knowledge is not related to the HTNFs' knowledge domain, its specialized capabilities might be
beneficial in using these alliances because they help in gaining a reputation in a particular knowledge domain and as a result better
upstream partners. They also protect a firm's knowledge from expropriation by partners in the “co-opetition” scenario of
horizontal alliances. When access to capabilities downstream of the value chain is the main driver of alliance formation, a broader
set of technological capabilities can increase HTNFs' bargaining power and gains in NPD. The findings help to clarify the role of new
firms' technological capabilities in determining the potential benefits and risks associated with strategic alliances especially when
it comes to NPD, a source of competitive advantage.
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